Quetiapine Extended Release Open-Label Treatment Associated Changes in Amygdala Activation and Connectivity in Anxious Depression: An fMRI Study

J Clin Psychopharmacol. 2016 Dec;36(6):562-571. doi: 10.1097/JCP.0000000000000600.

Abstract

Background: This study investigated extended release quetiapine (quetiapine XR) associated changes in functional MRI (fMRI) measures of task-induced amygdalar activation and resting state connectivity in anxious unipolar major depressive disorder (AMDD).

Methods: Anxious unipolar major depressive disorder patients (n = 15) (17-item Hamilton Depression Rating Scale (HAM-D) >18 and Hamilton Anxiety Scale (HAM-A) >18) and closely matched healthy control (HC) subjects were compared at baseline for task induced amygdala activation and resting state connectivity on fMRI. Subsequently, AMDD patients were treated for 8 weeks with open-label quetiapine XR. Weekly HAM-D and HAM-A ratings were obtained, and the fMRI scan was repeated at weeks 2 and 8. Changes in fMRI measures were calculated using repeated-measures analysis of variance and correlation with decrease in HAM-D and HAM-A scores was examined.

Results: At baseline, AMDD compared with HC exhibited increased task-induced left amygdalar activation (P = 0.05 clusterwise corrected) and decreased resting state amygdala-cortical and amygdala-pons connectivity (P < 0.05 clusterwise corrected). Quetiapine XR treatment was associated with significant decrease in HAM-D (df = 1,28; female [F] = 39; P = 0.001) and HAM-A scores (df = 1,28; F = 55; P = 0.001). The AMDD group showed increased amygdala-cortical connectivity (P < 0.05 [clusterwise corrected]) at week 2, which was maintained at week 8. At week 8, additional areas showed increased connectivity including insula and putamen. At 8 weeks, decrease in HAM-D scores correlated with increase in amygdala-mid cingulate and amygdala-cuneus connectivity (P = 0.05 [clusterwise corrected]). Decrease in HAM-A scores correlated with increase in amygdala-cuneus and parietal cortex connectivity (P = 0.05 [clusterwise corrected]).

Limitations: Small sample-size, open-label single-arm design, HC only tested at baseline, focused only on amygdala.

Conclusions: Quetiapine XR effects in the treatment of AMDD are associated with modulation of amygdala connectivity.

MeSH terms

  • Adult
  • Aftercare
  • Amygdala / drug effects*
  • Amygdala / physiopathology
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacology*
  • Anxiety Disorders / drug therapy*
  • Anxiety Disorders / epidemiology
  • Anxiety Disorders / physiopathology
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / physiopathology
  • Comorbidity
  • Delayed-Action Preparations
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / epidemiology
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Nerve Net / drug effects*
  • Nerve Net / physiopathology
  • Quetiapine Fumarate / administration & dosage
  • Quetiapine Fumarate / pharmacology*
  • Treatment Outcome
  • Young Adult

Substances

  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Quetiapine Fumarate